Free Trial

Glaxo: Success In Zantac Case

HEALTHCARE

Glaxo (GSK: A2 / A): Success in Illinois Trial


  • Glaxo wins jury verdict in Valadez case.
  • This is the first Zantac case to go to trial.
  • The next case (Williams) was dismissed before it commenced.


Keep reading...Show less
34 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Glaxo (GSK: A2 / A): Success in Illinois Trial


  • Glaxo wins jury verdict in Valadez case.
  • This is the first Zantac case to go to trial.
  • The next case (Williams) was dismissed before it commenced.


Keep reading...Show less